24 febrero 2015
Two widely used targeted therapy drugs— approved by the FDA for use in metastatic kidney cancer —are no more effective than a placebo in preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery, according to new research results.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/DD8o8MMnaWE/150224083316.htm
